title: Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
abstract: OBJECTIVE
  The objectives of this study were to determine whether the midazolam clearance predicted docetaxel pharmacokinetics, CA-125 change, and response and to assess the impact of cytochrome P450 (CYP) 3A5 and ATP-binding cassette, subfamily B, member 1 (ABCB1) genotypes on docetaxel pharmacokinetics and pharmacodynamics in ovarian or primary peritoneal cancer patients.
  
  
  METHODS
  Thirty-four patients with advanced ovarian and primary peritoneal cancer were administered docetaxel at 75 mg/m(2) as a 1-h infusion in combination with carboplatin IV over 30 min at a target AUC of 5 mg/ml min. Cycles were repeated every 21 days for 6 cycles. Midazolam was administered at 2 mg as a 30-min IV infusion the day prior to cycle one of docetaxel administration. Pharmacokinetic studies of docetaxel and CYP3A5 and ABCB1 genotype studies were performed.
  
  
  RESULTS
  There was an inverse relationship between midazolam clearance (CL) and CA-125 level after cycle 6 where a higher midazolam CL was associated with a CA-125 <10 U/ml (P = 0.007) and CA-125 <15 U/ml (P = 0.048). The CA-125 categories were associated with response achieved (complete response/partial response) (CR/PR), stable disease (SD), and progressive disease (PD) at the end of therapy (P = 0.0173). Docetaxel CL was not related to midazolam CL or genotype. Docetaxel exposure and genotypes were not related to toxicity or response (P > 0.05).
  
  
  CONCLUSIONS
  The midazolam CL predicted CA-125 levels and response that was independent of other factors including docetaxel pharmacokinetics. Future studies need to evaluate the mechanism for the relationship between midazolam CL and response in patients with ovarian cancer.
authors: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1013 Genetic Medicine Building, CB 7361, Chapel Hill, NC 27599, USA. zamboni@unc.edu
authors: William C
authors: WC
authors: Zamboni
authors: Austin J
authors: AJ
authors: Combest
authors: Julie A
authors: JA
authors: DeLoia
authors: Robert P
authors: RP
authors: Edwards
authors: Arlene S
authors: AS
authors: Bridges
authors: Beth A
authors: BA
authors: Zamboni
authors: Christine M
authors: CM
authors: Walko
authors: Angela Y C
authors: AY
authors: Yu
authors: Thomas C
authors: TC
authors: Krivak
authors: Joseph L
authors: JL
authors: Kelley
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001483:Base Sequence; D002853:Chromatography, Liquid; D017931:DNA Primers; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D016133:Polymerase Chain Reaction; D053719:Tandem Mass Spectrometry; D043823:Taxoids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D017931:DNA Primers; D043823:Taxoids; D000077143:Docetaxel